Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697811 · ClinicalTrials.gov registry record · Phase 3
DE-117 Spectrum 5 Study
A Phase 3 study of Primary Open-angle Glaucoma and Ocular Hypertension, sponsored by Santen.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT03697811 is a Phase 3 study of Primary Open-angle Glaucoma and Ocular Hypertension that has completed, run by Santen. The registered enrollment target is 107 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT03697811, a Phase 3 study of Primary Open-angle Glaucoma and Ocular Hypertension, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
Conditions Studied
Interventions
- DRUG DE-117 Ophthalmic Solution
Study Locations (20)
California
- Global Research Management - Glendale
- North Valley Eye Medical Group - Mission Hills
- Eye Research Foundation - Newport Beach
- North Bay Eye Associates - Petaluma
- Martel Eye Medical Group - Rancho Cordova
Georgia
- Dixon Eye Care - Albany
- Clayton Eye Clinical Research, LLC - Morrow
- Coastal Research Associates, LEC - Roswell
New York
- NYU Langone Health Department of Ophthalmology - New York
- Rochester Ophthalmological Group, PC - Rochester
- South Shore Eye Center - Wantagh
Florida
- Shettle Eye Research, Inc. - Largo
- International Eye Associates, PA - Ormond Beach
Missouri
- Tekwani Vision Center - St Louis
- Comprehensive Eye Care Ltd - Washington
North Carolina
- Asheville Eye Associates, PLLC - Asheville
- Mundorf Eye Center - Charlotte
Arizona
- Arizona Eye Center - Chandler
Connecticut
- Danbury Eye Physicians & Surgeons - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03697811
The ClinicalTrials.gov registry entry for NCT03697811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Open-angle Glaucoma and Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which DE-117 Ophthalmic Solution is the first listed.
NCT03697811 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT03697811 about?
NCT03697811 is a clinical study titled "DE-117 Spectrum 5 Study". Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
What is the current status of trial NCT03697811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2018-09-27. Estimated completion is 2022-01-13.
What conditions does trial NCT03697811 study?
This clinical trial studies the following conditions: Primary Open-angle Glaucoma and Ocular Hypertension.
What interventions are being tested in trial NCT03697811?
The interventions under investigation include: DE-117 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03697811?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03697811 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.